In people with cannabis use disorder, there may be little to no difference in the likelihood of adverse events with oxytocin compared with placebo (low-certainty evidence).
In plain wordsIn people with cannabis use disorder, adverse events may be about as likely with oxytocin as with placebo; the evidence is weak.
- Peptide
- Oxytocin
- Outcome
- No significant changeAdverse events with oxytocin versus placebo
- Study
n = 16
- Comparator
- Placebo
- Outcome group
- Adverse events · Mental health and mood
- Studied dose
- Dose not stated
Measurements
- Risk ratio
- 0.5 ratio
- adverse events, oxytocin versus placebo
- 95% CI lower
- 0.06 ratio
- adverse events
- 95% CI upper
- 4.47 ratio
- adverse events
Source sentences
or oxytocin (RR 0.50, 95% CI 0.06 to 4.47; 1 study, 16 participants)
1 context sentence(design, population, supporting numbers)
Pharmacotherapies for cannabis use disorder.